Exelixis
Buying intent
24 tracked signals | Top 15 topics are below | Marketing and HR are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Exelixis's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
16d ago
12d ago
18d ago
12d ago
24d ago
24d ago
12d ago
25d ago
25d ago
26d ago
16d ago
31d ago
25d ago
24d ago
18d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Exelixis
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileEvery Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts.
Top accounts researching Exelixis
names withheld on the public pageThese are companies whose own people brought up Exelixis unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
6,390 companies · 20,106 people are researching High-impact system
Exelixis's own team shows 2 signals on this topic. No one outside Exelixis has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Hiring75,708 cos · 411,263 people
- GTM Planning2,773 cos · 6,458 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Marketing — 2 people; HR / Talent — 2 people; Product — 1 person; Security — 1 person
What's been said
public posts by Exelixis's teamNo public post naming Exelixis has surfaced in the past year, so this is what Exelixis's own team is posting about publicly — their topics, in their words.
We’ve added some great folks to our team in the last few months, like Jenna Rodeawald , and I’m excited that we have space for a couple more as we gear up for launch. Reach out to learn more about the opportunities in our Alameda office!
May 2026Thank you, Ryan Murr , Branden Berns and the other excellent legal professionals at Gibson Dunn who worked with the Cytokinetics team so effectively during an historic week for the company.
May 2026#ESMO25 was a success! My focus was on intensive investigator meetings strategizing on the next wave of clinical trials for our assets. • I engaged in many discussions with leading global investigators on trial designs that incorporates the new ESMO data, focusing on: • Biomarker-Driven Trials: Designing studies to better identify the patients who will benefit most from emerging therapies. • Novel Combinations: Planning the subsequent steps for agents, moving them into earlier disease settings or combining them with other innovative modalities. • Global Collaboration: Coordinating efforts across continents to ensure efficient, impactful clinical programs that accelerate drug development. The collaborative spirit was truly inspiring, solidifying our shared commitment to expediting therapeutic innovation for patients worldwide. Huge thanks to the investigators, researchers, whose dedication made this year's ESMO a remarkable success. Back to our campus to turn strategy into action!
Oct 2025Strategic priorities
Earnings call; SEC filingsMarket Share; Research and Development
What changed recently
Earnings call; SEC filingsMarket Share; Research and Development